What are your outpatient surveillance strategies (biomarkers, imaging, symptoms) to monitor response to treatment for ATTR amyloidosis with cardiac involvement? 

I continue it indefinitely. Limited survival data shows a beneficial effect for at least 5 years with survival on the drug of 55% compared to 37% on placebo.

Elliot et al., PMID 34923848

However, if patients deteriorate dramatically on therapy and are class IV NYHA, I discuss with patients and family ...